Four FTSE AIM 100 Stocks Performing Well On Christmas Eve – SLN, CVSG, CRW And ASC

8 min read | December 24, 2019 02:01 PM GMT | By Team Kalkine Media
Silence Therapeutics Plc

Silence Therapeutics Plc (LON:SLN) is a London, United Kingdom based pharmaceuticals and biotechnology company, majorly involved in the research and development of pharmaceutical products based on RNA (ribonucleic acid) technology. This technology harnesses the body’s natural occurring mechanisms to create therapeutic effects within own cells of the body. Company’s pipeline basically includes various programmes under three core categories which are haematology, Cardiovascular diseases and rare diseases. Under Haematology, the different programmes include Beta Thalassaemia, which has completed the pre-clinical phase, Myelodysplastic Syndrome, which also has completed the Pre-clinical phase and an undisclosed indication which is in the discovery phase.

SLN Share Price Performance

(Source: Thomson Reuters) Daily Chart as on 24-December-19, before the close of the market

As on 24th December 2019, at 12:05 P.M Greenwich Mean Time, while writing, Silence Therapeutics Plc’s price of the stock was reported at GBX 402.00 per stock on the London Stock Exchange, an increase in the value of 2.03 per cent or GBX 8.00 per stock, as opposed to the last day’s closing price, which was reported at GBX 394.00 per stock. The company’s market capitalisation stood at a value of GBP 308.00 million in relation to the present market price of the share of the company.

Reportedly, Silence Therapeutics Plc’s stock has given an upside return of around 663.10 per cent in value in the last one year, from the price of GBX 52.68 per stock that the stocks set on December 24, 2018. The Silence Therapeutics Plc share has depicted an upside return in the previous half-year, of approximately 470.21 per cent from the price of GBX 70.50 per stock that the company’s stock achieved on June 24, 2019. Silence Therapeutics Plc’s stock though had lost value by 16.25 per cent, in the previous month from the price of GBX 480.00 per stock when the markets closed on November 25, 2019.

Company’s share beta was reported to be at a value of 1.10, which means that the movement of the share of Silence Therapeutics Plc, has been more volatile, in comparison with the movement of the comparative benchmark index in the last one year.

CVS Group Plc

CVS Group Plc (LON:CVS) is a Diss, United Kingdom headquartered veterinary service providing company. The organisation professes to be the biggest coordinated veterinary specialist organisation in the UK, operating more than 450 veterinary medical procedures all through England, Northern Ireland, Scotland and Wales and provides treatment to small animals, large animals as well as equine animals. The organisation has a veterinary analytic practice with four research centres, seven pet crematoria, Animal Direct - the company’s e-commerce portal, Pet Medic Recruitment – the company’s veterinary recruitment agency, the healthy pet club - company promoted largest preventive pet Healthcare scheme in the United Kingdom, VETisco - is the company’s veterinary instruments business and MiVetClub & VetShare - two pet buying groups supported by the company. Other than the above, the company also has its own brand MiPet brand of Pet food, therapeutics and associated products.

CVSG Share Price Performance

(Source: Thomson Reuters) Daily Chart as on 24-December-19, before the close of the market

As on 24th December 2019, at 12:10 P.M Greenwich Mean Time, while writing, CVS Group Plc’s price of the stock was reported at GBX 1166.00 per stock on the London Stock Exchange, an increase in the value of 1.39 per cent or GBX 16.00 per stock, as opposed to the last day’s closing price, which was reported at GBX 1150.00 per stock. The company’s market capitalisation stood at a value of GBP 812.00 million in relation to the present market price of the share of the company.

Reportedly, CVS Group Plc’s stock has given an upside return of around 83.48 per cent in value in the last one year, from the price of GBX 635.50 per stock that the stocks set on December 24, 2018. The CVS Group Plc share has depicted an upside return in the previous half-year, of approximately 79.25 per cent from the price of the stock of GBX 650.50 per stock that the company’s stock achieved on June 24, 2019. CVS Group Plc’s stock had also gained value by 11.15 per cent, in the previous month from the price of GBX 1049.00 per stock when the markets closed on November 25, 2019.

Company’s share beta was reported to be at a value of 0.83, which means that the movement of the share of CVS Group Plc, has been less volatile, in comparison with the movement of the comparative benchmark index in the last one year.

Craneware Plc

Craneware Plc (LON:CRW) is an Edinburgh, United Kingdom based healthcare services providing company that is engaged in the development, licensing and providing support using computer software to the core healthcare industry based in the United States of America. The company provides its services to brands such as Southampton Hospital, Firelands regional medical centre, Jupiter Medical centre as well as Ohio Health. The list of the company’s products includes Chargemaster Toolkit, Pharmacy Charge Link, Trisus Pricing Analyzer, Trisus Claims Informatics, Physician revenue toolkit, Trisus Healthcare Intelligence, Trisus Supply, Supply Assistant and online reference toolkit. The company has a Value Cycle tool that helps improve healthcare facilities their Financial Data, Operational Data as well as Clinical data by addressing various dimensions such as Quality of care, Patient satisfaction and engagement, Clinical outcomes, Operational efficiency as well as Risk management.

CRW Share Price Performance

(Source: Thomson Reuters) Daily Chart as on 24-December-19, before the close of the market

As on 24th December 2019, at 12:15 P.M Greenwich Mean Time, while writing, Craneware Plc’s price of the stock was reported at GBX 2440.00 per stock on the London Stock Exchange, an increase in the value of 6.09 per cent or GBX 140.00 per stock, as opposed to the last day’s closing price, which was reported at GBX 2300.00 per stock. The company’s market capitalisation stood at a value of GBP 626.00 million in relation to the present market price of the share of the company.

Reportedly, Craneware Plc’s stock has given an upside return of around 7.49 per cent in value in the last one year, from the price of GBX 2270.00 per stock that the stocks set on December 24, 2018. The Craneware Plc share has depicted a downside return in the previous half-year, of approximately 18.94 per cent from the price of the stock of GBX 3010.00 per stock that the company’s stock achieved on June 24, 2019. Craneware Plc’s stock had also lost value by 2.20 per cent, in the previous month from the price of GBX 2495.00 per stock when the markets closed on November 25, 2019.

Company’s share beta was reported to be at a value of 1.18, which means that the movement of the share of Craneware Plc, has been more volatile, in comparison with the movement of the comparative benchmark index in the last one year.

Asos Plc

Asos Plc (LON:ASC) is a British online fashion and cosmetic retailer with an active presence in the UK, US and Continental Europe. Apart from being a fashion company, the group calls itself a technology company and is one of the leading fashions stops globally. Around 60 per cent of the products sold are exclusively through its platform, and the company operates its own brand of clothes as well. The company’s operations are differentiated in three operating segments: Retail sales, Delivery receipts and Third-party revenues.

ASC Share Price Performance

(Source: Thomson Reuters) Daily Chart as on 24-December-19, before the close of the market

As on 24th December 2019, at 12:20 P.M Greenwich Mean Time, while writing, Asos Plc’s price of the stock was reported at GBX 3325.00 per stock on the London Stock Exchange, an increase in the value of 3.13 per cent or GBX 101.00 per stock, as opposed to the last day’s closing price, which was reported at GBX 3224.00 per stock. The company’s market capitalisation stood at a value of GBP 2.706 billion in relation to the present market price of the share of the company.

Reportedly, Asos Plc’s stock has given an upside return of around 46.15 per cent in value in the last one year, from the price of GBX 2275.00 per stock that the stocks set on December 24, 2018. The Asos Plc share has depicted an upside return in the previous half-year, of approximately 16.95 per cent from the price of the stock of GBX 2843.00 per stock that the company’s stock achieved on June 24, 2019. Asos Plc’s stock had also gained value by 5.93 per cent, in the previous month from the price of GBX 3139.00 per stock when the markets closed on November 25, 2019.

Company’s share beta was reported to be at a value of 1.51, which means that the movement of the share of Asos Plc, has been more volatile, in comparison with the movement of the comparative benchmark index in the last one year.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next